Sun Pharma Settles Patent Litigation With Allergan, Ironwood
The patent litigation was for a generic version of Linzess.
India’s largest drugmaker Sun Pharmaceutical Industries Ltd. today said it reached an agreement to resolve a patent litigation with Ironwood Pharmaceuticals and Allergan for Linzess generic in the U.S.
The patent litigation was brought in response to Sun Pharma’s abbreviated new drug application seeking approval to market a generic version of Linzess prior to the expiration of the companies’ applicable patents, the Indian pharma major said in an exchange filing.
Linzess, is a prescription medication used to treat irritable bowel syndrome with constipation.
As part of the agreement, Ironwood Pharma and Allergan will grant Sun Pharma subsidiaries a license to market the generic version of the drug in the U.S. effective from Feb 1, 2031 or earlier under certain circumstances, the filing said.
Following the settlement, all pending litigation between Sun Pharma and the two companies regarding the said patent will be dismissed. The agreement is subject to customary regulatory approvals, Sun Pharma added.